Oncology Drug– category –

Nuclear medicine next decade: shift from β (177Lu) to α (225Ac, 212Pb). α has 100× cytotoxicity, short range protects normal tissue. Pipelines: 225Ac-PSMA, 225Ac-FAP, 225Ac-DOTATATE (RYZ101), 212Pb-DOTAMTATE. New targets (FAP, GD2, HER2, αvβ6). Manufacturing wall (Oak Ridge, Karlsruhe, PSI, JAEA). Final volume.

Comparison of nuclear medicine competitors (Lantheus, Bayer, Telix, Lilly × Mariana, BMS × RayzeBio, AZ × Fusion) across 5 axes: diagnostic vs treatment, target molecules, isotopes, manufacturing infrastructure, partnerships. Emerging specialists (Aktis, Convergent, Perspective, Curasight, Clarity) and industry reshuffling scenarios. Vol. 2.

Novartis Pluvicto (mCRPC, $1B+ annual revenue) and Lutathera (NET) clinical and commercial success moved nuclear medicine from niche to mainstream. Short isotope half-life and specialized facility requirements make Vertical Integration (production-synthesis-distribution-delivery chain) decisive competitive advantage. Endocyte acquisition $2.1B, Point Biopharma $1.4B, 14-site global manufacturing network. Vol. 1.

Structural comparison of CAR-T's three commercialization paths (autologous, allogeneic, in vivo) across 7 axes. Market projection: $16.5B in 2030, $35B in 2035, with in vivo's late-decade growth. Final volume.

Comparing 5 in vivo CAR-T companies (Capstan, Umoja, Orna, Renagade, Sana) on technology platform (LNP-mRNA, LV, circular RNA, multi-organ LNP), indication focus (autoimmune vs cancer), strategic partners (Pfizer, Lilly, Merck). Vol. 2.

April 21, 2026 Eli Lilly to acquire Kelonia Therapeutics for up to $7B—the largest in vivo CAR-T M&A signaling pharma majors' serious entry. Kelonia's PreciseTarget LNP delivers CAR mRNA to T cells in vivo, softening ex vivo CAR-T's three walls (manufacturing time, cost, toxicity) simultaneously. Vol. 1.

Nagaraja et al. Nature 2026/4/16: chronic colitis leaves AP-1-dependent epigenetic memory in colonic stem cell chromatin that persists for 100+ days. SHARE-TRACE proves clonal inheritance through stem cell divisions. Memory + APC mutation cooperatively accelerates tumor formation; AP-1 inhibition eliminates acceleration. New IBD-cancer prevention paradigm. Final volume.

Cell April 2026 paper used human iPSC-derived cerebellar organoids + CRISPR to reproduce all four medulloblastoma subtypes (WNT, SHH, Group 3, Group 4) in real time. Cell of origin for each subtype directly confirmed. Vismodegib and BET inhibitor responses validated in subtype-specific manner. Personalized-therapy organoid proof of concept. Vol. 2.

Reyes et al. Cell May 2026: PDAC's benign-to-malignant transition happens in a rare progenitor-like cell population that assembles a self-reinforcing niche. Tumor-driving and tumor-suppressing programs (p53, CDKN2A, SMAD4) co-activate in these cells. KRAS inhibition or p53 activation collapses the niche and delays malignancy. Vol. 1.

Science April 23, 2026 (Ciucci et al.) finally answered why the heart almost never develops cancer. Three experimental systems — genetic mouse model + heterotopic heart transplantation unloading + engineered heart tissues — established that mechanical load directly suppresses cancer cell proliferation. Mechanism: Nesprin-2 → histone methylation (H3K9me3) → chromatin compaction → reduced proliferation. Opens a new therapeutic axis: mechanical-stimulation therapy.

Series finale. Same metastatic RCC, contrasting designs: PERFORM (healthy donor, ipi/nivo) vs TACITO (ICI complete-responder donor, pembro+axitinib). The cross-trial Segatella copri context-dependent toxicity discovery (drives toxicity ONLY under dual ICI), the three-layer commercial map (Seres/Vedanta/Exeliom; Locus/Eligo; rational consortia), and structural implications for the global ecosystem. The clinical-translation year of FMT/LBP, synthesized.

Building on Volume 1, we dissect the convergent finding across the three April 2026 Nature Medicine trials: FMT works because patients lose their own deleterious bacteria, not because they acquire donor bacteria. FMT-LUMINate's mouse reverse-experiment proved causality. Mechanism: tryptophan/kynurenine pathway disturbance, IDO/AhR axis, regulatory T-cell expansion. Vol. 2 of the series.

In April 2026, Nature Medicine Vol. 32 No. 4 published three FMT-plus-immunotherapy trials in a single issue: 80% ORR in NSCLC, and a doubling of progression-free survival in metastatic RCC (24.0 vs 9.0 months, HR 0.50). But the deeper significance lies not in the numbers — it is the shared mechanistic finding that responders selectively lost their own deleterious bacteria, rather than acquiring beneficial bacteria from the donor. Volume 1 of our series surveys all three trials and what their simultaneous publication means.

From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, ...

In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gai...

In Parts 1–3, we reviewed CDK7/8 and CDK9. In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of ge...

In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from pa...

In Part 1, we reviewed the fundamentals of transcription and the CDK family. In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcripti...

This series focuses on the transcriptional machinery as an emerging target for cancer therapy, highlighting CDK (Cyclin-Dependent Kinases) families involved in transcription and BRD4. This series focuses on the transcriptional machinery ...

This series will explore the latest drug discovery trends targeting the transcriptional machinery. This series will explore the latest drug discovery trends targeting the transcriptional machinery. In Part 1, we provide an introduction: ...